Prothena Number of Employees 2011-2022 | PRTA
Prothena number of employees from 2011 to 2022. Number of employees can be defined as a measure of financial performance calculated as operating cash flow minus capital expenditures, expressed on a per share basis
| Prothena Annual Number of Employees |
| 2021 |
82 |
| 2020 |
66 |
| 2019 |
51 |
| 2018 |
59 |
| 2017 |
125 |
| 2016 |
96 |
| 2015 |
66 |
| 2014 |
46 |
| 2013 |
39 |
| 2012 |
30 |
| 2011 |
|
| 2010 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$1.305B |
$0.201B |
|
Prothena Corp. plc, being a clinical-stage neuroscience company, focused on the development of novel therapeutic therapies for life-threatening diseases. Its wholly owned programs include birtamimab for the potential treatment of AL amyloidosis, PRX004 for the potential treatment of ATTR amyloidosis and a portfolio of programs for the potential treatment of Alzheimer's disease including PRX012 that targets A?.?Prothena is also developing candidates in collaboration with bigwigs like Roche and Bristol-Myers Squibb. These programs include prasinezumab, in collaboration with Roche for the potential treatment of Parkinson's disease and other related synucleinopathies, and programs that target tau, TDP-43 and an undisclosed target in collaboration with Bristol-Myers Squibb for the potential treatment of Alzheimer's disease, amyotrophic lateralsclerosis, etc. It sold PRX004 and the broader ATTR amyloidosis program to Novo Nordisk. It derives revenues from license, development & commercialization agreements.
|
